Abstract
IgA nephropathy (IgAN) is the most common primary glomerulonephritis. Up to 40% of patients with IgAN are at risk of progressing to end-stage kidney disease (ESKD); proteinuria is the strongest predictor of progression. Endothelin A receptor (ETA) activation promotes proteinuria, along with kidney inflammation and fibrosis. Atrasentan, a potent and selective ETA antagonist, has been studied in >5,000 patients in a global phase 3 outcome clinical trial in patients with diabetic kidney disease who were on a maximum tolerated dose of RAS inhibitor (RASi).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
